The Efficacy of Danofloxacin in the Therapy of Acute Bacterial Pneumonia in Housed Beef Cattle

A Summary


  • S. T. Tolling Animal Health Group, Pfizer, Inc, New York, U.S.A.
  • H. Barthel Animal Health Division, Pfizer, Inc, Karlsruhe, Germany
  • C. J. Giles Central Research Division, Pfizer, Inc, Sandwich, U.K.
  • M. Isla Animal Health Division, Pfizer, Inc, Madrid, Spain
  • A. Mencarelli Animal Health Division, Pfizer, Inc, Rome, Italy
  • C. Thomasson European Clinical Development, Pfizer, Inc, Orsay, France



Danofloxacin, respiratory disease, pharmacokinetic studies, acute pneumonia, oxytetracycline, trimethoprim/sulpha


Danofloxacin* is an antimicrobial of the fluoroquinolone class, and has shown potent in vitro activity against the major bacterial pathogens involved in respiratory disease, Pasteurella haemolytica and Pasteurella multocida(1). Pharmacokinetic studies with danofloxacin in cattle have demonstrated an attractive profile. The drug is rapidly absorbed and distributed to respiratory tract tissues and secretions following intramuscular or subcutaneous administration ( 2, 3) . This paper summarizes the results of 11 studies in beef cattle conducted in Europe. The efficacy of danofloxacin against naturally occurring outbreaks of acute pneumonia was evaluated in comparison with oxytetracycline and trimethoprim/sulpha.

Spanish and French summaries on PDF.






Respiratory Disease / Immunology